Molecular mechanisms of arsenic carcinogenesis

Molecular and Cellular Biochemistry

Volumn 255, Issue 1-2, 2004, Pages 57-66

  Huang, Chuanshu ^a   Ke, Qingdong ^a   Costa, Max ^a   Shi, Xianglin ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

Author keywords

Arsenic; Carcinogenesis; Gene expression; Genetic toxicity; Kinase; Methylation; Reactive oxygen species; Signal transduction

Indexed keywords

ARSENIC; ARSENIC TRIOXIDE; DNA; PROTEIN P53; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR;

CANCER SUSCEPTIBILITY; CHEMICAL CARCINOGENESIS; CHEMICAL MUTAGENESIS; DNA DAMAGE; DNA METHYLATION; DNA REPAIR; DNA SYNTHESIS INHIBITION; ENVIRONMENTAL EXPOSURE; EPIGENETICS; GENE EXPRESSION; GENOTOXICITY; HUMAN; METAL METABOLISM; MOLECULAR BIOLOGY; NONHUMAN; OXIDATIVE STRESS; REVIEW; SIGNAL TRANSDUCTION; TOXICITY TESTING;

ANIMALS; ARSENIC; CELL TRANSFORMATION, NEOPLASTIC; CRICETINAE; CYTOKINES; DNA DAMAGE; DNA REPAIR; ENVIRONMENTAL POLLUTANTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MUTAGENS; ONCOGENES; OXIDATIVE STRESS; PROTEIN KINASES; RABBITS; RATS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 0742306716     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:MCBI.0000007261.04684.78     Document Type: Review

References (166)

1. 3) in the treatment of acute promyelocytic leukemia. J Biol Regul Homeost Agents 13: 195-200, 1999
2. Agis H, Weltermann A, Mitterbauer G, Thalhammer R, Edelhauser M, Seewann HL, Valent P, Lechner K, Fonatsch C, Geissler K: Successful treatment with arsenic trioxide of a patient with ATRA-resistant relapse of acute promyelocytic leukemia. Ann Hematol 78: 329-332, 1999
3. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, Chen Y, Zhou L, Fang ZW, Wang YT, Ma J, Zhang P, Zhang TD, Chen SJ, Chen Z, Wang ZY: Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89: 3354-3360, 1997
4. NRC: National Research Council Report: Arsenic in the Drinking Water. Washington, DC: National Academy Press, 1999
5. Germolec DR, Spalding J, Yu HS, Chen GS, Simeonova PP, Humble MC, Bruccoleri A, Boorman GA, Foley JF, Yoshida T, Luster MI: Arsenic enhancement of skin neoplasia by chronic stimulation of growth factors. Am J Pathol 153: 1775-1785, 1998
6. Simeonova PP, Luster MI: Mechanisms of arsenic carcinogenicity: Genetic or epigenetic mechanisms? J Environ Pathol Toxicol Oncol 19: 281-286, 2000
7. Ding M, Shi X, Castranova V, Vallyathan V: Predisposing factors in occupational lung cancer: Inorganic minerals and chromium. J Environ Pathol Toxicol Oncol 19: 129-138, 2000
8. Morales KH, Ryan L, Kuo TL, Wu MM, Chen CJ: Risk of internal cancers from arsenic in drinking water. Environ Health Perspect 108: 655-661, 2000
9. Steinmaus C, Moore L, Hopenhayn-Rich C, Biggs ML, Smith AH: Arsenic in drinking water and bladder cancer. Cancer Invest 18: 174-182, 2000
10. Barrett JC, Lamb PW, Wang TC, Lee TC: Mechanisms of arsenic-induced cell transformation. Biol Trace Elem Res 21: 421-429, 1989
11. Brown JL, Kitchin KT: Arsenite, but not cadmium, induces ornithine decarboxylase and heme oxygenase activity in rat liver: Relevance to arsenic carcinogenesis. Cancer Lett 98: 227-231, 1996
12. Rossman TG: Molecular and genetic toxicology of arsenic. In: J. Rose (ed). Environmental Toxicology: Current Developments. Gorden and Breach Science Publishers, Amsterdam, 1998, pp 171-187
13. Kroes R, van Logten MJ, Berkvens JM, de Vries T, van Esch GJ: Study on the carcinogenicity of lead arsenate and sodium arsenate and on the possible synergistic effect of diethylnitrosamine. Food Cosmet Toxicol 12: 671-679, 1974
14. Thorgeirsson UP, Dalgard DW, Reeves J, Adamson RH: Tumor incidence in a chemical carcinogenesis study of nonhuman primates. Regul Toxicol Pharmacol 19: 130-151, 1994
15. Byron WR, Bierbower GW, Brouwer JB, Hansen WH: Pathologic changes in rats and dogs from two-year feeding of sodium arsenite or sodium arsenate. Toxicol Appl Pharmacol 10: 132-147, 1967
16. Brown KG, Guo HR, Kuo TL, Greene HL: Skin cancer and inorganic arsenic: uncertainty-status of risk. Risk Anal 17: 37-42, 1997
17. Chappell WR, Beck BD, Brown KG, Chaney R, Cothern R, Cothern CR, Irgolic KJ, North DW, Thornton I, Tsongas TA: Inorganic arsenic: a need and an opportunity to improve risk assessment. Environ Health Perspect 105: 1060-1067, 1997
18. Waalkes MP, Fox DA, States JC, Patierno SR, McCabe MJ Jr: Metals and disorders of cell accumulation: Modulation of apoptosis and cell proliferation. Toxicol Sci 56: 255-261, 2000
19. Knowles FC, Benson AA: The enzyme inhibitory form of inorganic arsenic. Z Gesamte Hyg 30: 625-626, 1984
20. Bettley FR, O'Shea JA: The absorption of arsenic and its relation to carcinoma. Br J Dermatol 92: 563-568, 1975
21. Landolph JR: Molecular mechanisms of transformation of C3H/10T1/2 C1 8 mouse embryo cells and diploid human fibroblasts by carcinogenic metal compounds. Environ Health Perspect 102: 119-125, 1994
22. Chen CJ, Wang CJ: Ecological correlation between arsenic level in well water and age-adjusted mortality from malignant neoplasms. Cancer Res 50: 5470-5474, 1990
23. International Agency for Research on Cancer (IARC): IARC Monograph on Evaluation of Carcinogenic Risk to Humans. Suppl, 1980, pp 23-29
24. Chan PC, Huff J: Arsenic carcinogenesis in animals and in humans: Mechanistic, experimental, and epidemiological evidence. Environ Carcin Ecotox Rev C15: 83-122, 1997
25. Environmental Protection Agency, 40 GFR Part 9, 141 and 142. National primary drinking water regulations. Arsenic and clarification to compliance and new source contaminants monitoring. Final rule. Fed Regist 66: 6975-7066, 2001
26. Bagla P, Kaiser J: India's spreading health crisis draws global arsenic experts. Science 274: 174-175, 1996
27. Das D, Chatterjee A, Samanta G, Mandal B, Chowdhury TR, Samanta G, Chowdhury PP, Chanda C, Basu G, Lodh D: Arsenic contamination in groundwater in six districts of West Bengal, India: The biggest arsenic calamity in the world. Analyst 119: 168N-170N, 1994
28. Mazumder DN, Das Gupta J, Santra A, Pal A, Ghose A, Sarkar S: Chronic arsenic toxicity in West Bengal - the worst calamity in the world. J Indian Med Assoc 96: 4-7, 18, 1998
29. Saha DP: Arsenic poisoning in West Bengal. Science 274: 1287, 1996
30. Subramanian KS: Arsenic poisoning in West Bengal. Science 274: 1287-1288, 1996
31. Schwartz RA: Arsenic and the skin. Int J Dermatol 36: 241-250, 1997
32. Wong SS, Tan KC, Goh CL: Cutaneous manifestations of chronic arsenicism: Review of seventeen cases. J Am Acad Dermatol 38: 179-185, 1998
33. Tsuda T, Nagira T, Yamamoto M, Kurumatani N, Hotta N, Harada M, Aoyama H: Malignant neoplasms among residents who drank well water contaminated by arsenic from a king's yellow factory. J Uoeh 11: 289-301, 1989
34. Bates MN, Smith AH, Hopenhayn-Rich C: Arsenic ingestion and internal cancers: A review. Am J Epidemiol 135: 462-476, 1992
35. National Institute for Occupational Safety and Health, National Occupational Exposure Survey (1980-1983), Department of Health and Human Services, Cincinnati, OH, 1984
36. Lansdown AB: Physiological and toxicological changes in the skin resulting from the action and interaction of metal ions. Crit Rev Toxicol 25: 397-462, 1995
37. Luchtrath H: The consequences of chronic arsenic poisoning among Moselle wine growers. Pathoanatomical investigations of post-mortem examinations performed between 1960 and 1977. J Cancer Res Clin Oncol 105: 173-182, 1983
38. Philipp R: Arsenic exposure: Health effects and the risk of cancer. Rev Environ Health 5: 27-57, 1985
39. Germolec DR, Spalding J, Yu HS, Chen GS, Simeonova PP, Humble MC, Bruccoleri A, Boorman GA, Foley JF, Yoshida T, Luster MI: Arsenic enhancement of skin neoplasia by chronic stimulation of growth factors. Am J Pathol 153: 1775-1785, 1998
40. Tseng WP, Chu HM, How SW, Fong JM, Lin CS, Yeh S: Prevalence of skin cancer in an endemic area of chronic arsenicism in Taiwan. J Natl Cancer Inst 40: 453-463, 1968
41. Bates MN, Smith AH, Cantor KP: Case-control study of bladder cancer and arsenic in drinking water. Am J Epidemiol 141: 523-530, 1995
42. Chen CJ, Chen CW, Wu MM, Kuo TL: Cancer potential in liver, lung, bladder and kidney due to ingested inorganic arsenic in drinking water. Br J Cancer 66: 888-892, 1992
43. Chiou HY, Hsueh YM, Liaw KF, Horng SF, Chiang MH, Pu YS, Lin JS, Huang CH, Chen CJ: Incidence of internal cancers and ingested inorganic arsenic: A seven-year follow-up study in Taiwan. Cancer Res 55: 1296-1300, 1995
44. Morris RD: Drinking water and cancer. Environ Health Perspect 103(suppl 8): 225-231, 1995
45. Tsuda T, Babazono A, Yamamoto E, Kurumatani N, Mino Y, Ogawa T, Kishi Y, Aoyama H: Ingested arsenic and internal cancer: A historical cohort study followed for 33 years. Am J Epidemiol 141: 198-209, 1995
46. Scott N, Hatlelid KM, MacKenzie NE, Carter DE: Reactions of arsenic(III) and arsenic(V) species with glutathione. Chem Res Toxicol 6: 102-106, 1993
47. Yamauchi H, Yamamura Y: Concentration and chemical species of arsenic in human tissue. Bull Environ Contam Toxicol 31: 267-270, 1983
48. Lindgren A, Vahter M, Dencker L: Autoradiographic studies on the distribution of arsenic in mice and hamsters administered 74As-arsenite or -arsenate. Acta Pharmacol Toxicol (Copenh) 51: 253-265, 1982
49. Goyer RA: Toxic effects of metals. In: C.D. Klaassen, M.O. Amdur, J. Doull (eds). Toxicology, The Basic Science of Poisons. Macmillan Publishing Company, New York, 1986, pp 582-635
50. Lerman SA, Clarkson TW, Gerson RJ: Arsenic uptake and metabolism by liver cells is dependent on arsenic oxidation state. Chem Biol Interact 45: 401-406, 1983
51. 2+: Studies with phenylarsine oxide in thyroid plasma membrane. Biochem J 321: 383-388, 1997
52. Cavigelli M, Li WW, Lin A, Su B, Yoshioka K, Karin M: The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase. Embo J 15: 6269-6279, 1996
53. Klemperer NS, Pickart CM: Arsenite inhibits two steps in the ubiquitin-dependent proteolytic pathway. J Biol Chem 264: 19245-19252 1989
54. Bertolero F, Pozzi G, Sabbioni E, Saffiotti U: Cellular uptake and metabolic reduction of pentavalent to trivalent arsenic as determinants of cytotoxicity and morphological transformation. Carcinogenesis 8: 803-808, 1987
55. Snow ET: Metal carcinogenesis: Mechanistic implications. Pharmacol Ther 53: 31-65, 1992
56. Vahter M, Marafante E, Dencker L: Metabolism of arsenobetaine in mice, rats and rabbits. Sci Total Environ 30: 197-211, 1983
57. Buchet JP, Lauwerys R, Roels H: Comparison of the urinary excretion of arsenic metabolites after a single oral dose of sodium arsenite, monomethylarsonate, or dimethylarsinate in man. Int Arch Occup Environ Health 48: 71-79, 1981
58. Tam GK, Charbonneau SM, Bryce F, Pomroy C, Sandi E: Metabolism of inorganic arsenic (74As) in humans following oral ingestion. Toxicol Appl Pharmacol 50: 319-322, 1979
59. Marafante E, Vahter M, Norin H, Envall J, Sandstrom M, Christakopoulos A, Ryhage R: Biotransformation of dimethylarsinic acid in mouse, hamster and man. J Appl Toxicol 7: 111-117, 1987
60. Styblo M, Del Razo LM, Vega L, Germolec DR, LeCluyse EL, Hamilton GA, Reed W, Wang C, Cullen WR, Thomas DJ: Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells. Arch Toxicol 74: 289-299, 2000
61. Petrick JS, Ayala-Fierro F, Cullen WR, Carter DE, Aposhian HV: Monomethylarsonous acid (MMA(III)) is more toxic than arsenite in Chang human hepatocytes. Toxicol Appl Pharmacol 163: 203-207, 2000
62. Goering PL, Aposhian HV, Mass MJ, Cebrian M, Beck BD, Waalkes MP: The enigma of arsenic carcinogenesis: Role of metabolism. Toxicol Sci 49: 5-14, 1999
63. Aposhian HV: Arsenic toxicology: does methylation of arsenic species have an evolutionary significance? Metal Ions Biol Med 4: 399-401, 1996
64. Drinkwater NR, Bennett LM: Genetic control of carcinogenesis in experimental animals. Prog Exp Tumor Res 33: 1-20, 1991
65. Drinkwater NR: Experimental models and biological mechanisms for tumor promotion. Cancer Cells 2: 8-15, 1990
66. Ishinishi N, Kodama Y, Nobutomo K, Hisanaga A: Preliminary experimental, study on carcinogenicity of arsenic trioxide in rat lung. Environ Health Perspect 19: 191-196, 1977
67. Lee TC, Tanaka N, Lamb PW, Gilmer TM, Barrett JC: Induction of gene amplification by arsenic. Science 241: 79-81, 1988
68. Lerda D: Sister-chromatid exchange (SCE) among individuals chronically exposed to arsenic in drinking water. Mutat Res 312: 111-120, 1994
69. Li JH, Rossman TG: Inhibition of DNA ligase activity by arsenite: A possible mechanism of its comutagenesis. Mol Toxicol 2: 1-9, 1989
70. Li JH, Rossman TG: Mechanism of comutagenesis of sodium arsenite with n-methyl-n-nitrosourea. Biol Trace Elem Res 21: 373-381, 1989
71. Barchowsky A, Dudek EJ, Treadwell MD, Wetterhahn KE: Arsenic induces oxidant stress and NF-kappa B activation in cultured aortic endothelial cells. Free Radic Biol Med. 21: 783-790, 1996
72. Lynn S, Gurr JR, Lai HT, Jan KY: NADH oxidase activation is involved in arsenite-induced oxidative DNA damage in human vascular smooth muscle cells. Circ Res 86: 514-519, 2000
73. Liu F, Jan KY: DNA damage in arsenite- and cadmium-treated bovine aortic endothelial cells. Free Radic Biol Med 28: 55-63, 2000
74. Barchowsky A, Klei LR, Dudek EJ, Swartz HM, James PE: Stimulation of reactive oxygen, but not reactive nitrogen species, in vascular endothelial cells exposed to low levels of arsenite. Free Radic Biol Med 27: 1405-1412, 1999
75. Hei TK, Liu SX, Waldren C: Mutagenicity of arsenic in mammalian cells: Role of reactive oxygen species. Proc Natl Acad Sci USA 95: 8103-8107, 1998
76. Wang TS, Kuo CF, Jan KY, Huang H: Arsenite induces apoptosis in Chinese hamster ovary cells by generation of reactive oxygen species. J Cell Physiol 169: 256-268, 1996
77. Liu SX, Athar M, Lippai I, Waldren C, Hei TK: Induction of oxyradicals by arsenic: Implication for mechanism of genotoxicity. Proc Natl Acad Sci USA 98: 1643-1648, 2001
78. Flora SJ: Arsenic-induced oxidative stress and its reversibility following combined administration of N-acetylcysteine and meso 2,3-dimercaptosuccinic acid in rats. Clin Exp Pharmacol Physiol 26: 865-869, 1999
79. Shackelford RE, Kaufmann WK, Paules RS: Oxidative stress and cell cycle checkpoint function. Free Radic Biol Med 28: 1387-1404, 2000
80. Zhong W, Oberley LW, Oberley TD, St Clair DK: Suppression of the malignant phenotype of human glioma cells by overexpression of manganese superoxide dismutase. Oncogene 14: 481-490, 1997
81. Bolton JL, Trush MA, Penning TM, Dryhurst G, Monks TJ: Role of quinones in toxicology. Chem Res Toxicol 13: 135-160, 2000
82. Bolton JL, Pisha E, Zhang F, Qiu S: Role of quinoids in estrogen carcinogenesis. Chem Res Toxicol 11: 1113-1127, 1998
83. Chen Y, Liu X, Pisha E, Constantinou AI, Hua Y, Shen L, van Breemen RB, Elguindi EC, Blond SY, Zhang F, Bolton JL: A metabolite of equine estrogens, 4-hydroxyequilenin, induces DNA damage and apoptosis in breast cancer cell lines. Chem Res Toxicol 13: 342-350, 2000
84. Khan AU, Kovacic D, Kolbanovskiy A, Desai M, Frenkel K, Geacintov NE: The decomposition of peroxynitrite to nitroxyl anion (NO-) and singlet oxygen in aqueous solution. Proc Natl Acad Sci USA 97: 2984-2989, 2000
85. Xu Y, Krishnan A, Wan XS, Majima H, Yeh CC, Ludewig G, Kasarskis EJ, St Clair DK: Mutations in the promoter reveal a cause for the reduced expression of the human manganese superoxide dismutase gene in cancer cells. Oncogene 18: 93-102, 1999
86. Perkins C, Kim CN, Fang G, Bhalla KN: Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L). Blood 95: 1014-1022, 2000
87. Rossman TG, Stone D, Molina M, Troll W: Absence of arsenite mutagenicity in E. coli and Chinese hamster cells. Environ Mutagen 2: 371-379, 1980
88. Rossman T, Meyn MS, Troll W: Effects of sodium arsenite on the survival of UV-irradiated Escherichia coli: Inhibition of a recA-dependent function. Mutat Res 30: 157-162, 1975
89. Wiseman H, Halliwell B: Damage to DNA by reactive oxygen and nitrogen species: Role in inflammatory disease and progression to cancer. Biochem J 313: 17-29, 1996
90. Li JJ, Oberley LW, Fan M, Colburn NH: Inhibition of AP-1 and NF-kappaB by manganese-containing superoxide dismutase in human breast cancer cells. Faseb J 12: 1713-1723, 1998
91. Sen CK, Packer L: Antioxidant and redox regulation of gene transcription. Faseb J 10: 709-720, 1996
92. Lander HM: An essential role for free radicals and derived species in signal transduction. Faseb J 11: 118-124, 1997
93. Corsini E, Asti L, Viviani B, Marinovich M, Galli CL: Sodium arsenate induces overproduction of interleukin-1alpha in murine keratinocytes: Role of mitochondria. J Invest Dermatol 113: 760-765, 1999
94. Kaltreider RC, Pesce CA, Ihnat MA, Lariviere JP, Hamilton JW: Differential effects of arsenic(III) and chromium(VI) on nuclear transcription factor binding. Mol Carcinog 25: 219-229, 1999
95. Wijeweera JB, Gandolfi AJ, Parrish A, Lantz RC: Sodium arsenite enhances AP-1 and NFkappaB DNA binding and induces stress protein expression in precision-cut rat lung slices. Toxicol Sci 61: 283-294, 2001
96. Germolec DR, Yoshida T, Gaido K, Wilmer JL, Simeonova PP, Kayama F, Burleson F, Dong W, Lange RW, Luster MI: Arsenic induces overexpression of growth factors in human keratinocytes. Toxicol Appl Pharmacol 141: 308-318, 1996
97. Hamadeh HK, Vargas M, Lee E, Menzel DB: Arsenic disrupts cellular levels of p53 and mdm2: A potential mechanism of carcinogenesis. Biochem Biophys Res Commun 263: 446-449, 1999
98. Roussel RR, Barchowsky A: Arsenic inhibits NF-kappaB-mediated gene transcription by blocking IkappaB kinase activity and IkappaBalpha phosphorylation and degradation. Arch Biochem Biophys 377: 204-212, 2000
99. Estrov Z, Manna SK, Harris D, Van Q, Estey EH, Kantarjian HM, Talpaz M, Aggarwal BB: Phenylarsine oxide blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, and induces apoptosis of acute myelogenous leukemia cells. Blood 94: 2844-2853, 1999
100. Rew DA: Cell and molecular mechanisms of pathogenesis and treatment of cancer. Postgrad Med J 74: 77-88, 1998
101. Steller H: Mechanisms and genes of cellular suicide. Science 267: 1445-1449, 1995
102. Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY, Jin XL, Tang W, Li XS, Xong SM, Shen ZX, Sun GL, Ma J, Zhang P, Zhang TD, Gazin C, Naoe T, Chen SJ, Wang ZY, Chen Z: In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 88: 1052-1061, 1996
103. Del Razo LM, Quintanilla-Vega B, Brambila-Colombres E, Calderon-Aranda ES, Manno M, Albores A: Stress proteins induced by arsenic. Toxicol Appl Pharmacol 177: 132-148, 2001
104. Smith KR, Klei LR, Barchowsky A: Arsenite stimulates plasma membrane NADPH oxidase in vascular endothelial cells. Am J Physiol Lung Cell Mol Physiol 280: L442-449, 2001
105. Rossman TG, Uddin AN, Burns FJ, Bosland MC: Arsenite is a cocarcinogen with solar ultraviolet radiation for mouse skin: An animal model for arsenic carcinogenesis. Toxicol Appl Pharmacol 176: 64-71, 2001
106. Gurr JR, Lin YC, Ho IC, Jan KY, Lee TC: Induction of chromatid breaks and tetraploidy in Chinese hamster ovary cells by treatment with sodium arsenite during the G2 phase. Mutat Res 319: 135-142, 1993
107. Wang TS, Huang H: Active oxygen species are involved in the induction of micronuclei by arsenite in XRS-5 cells. Mutagenesis 9: 253-257, 1994
108. Dong JT, Luo, XM: Arsenic-induced DNA-strand breaks associated with DNA-protein crosslinks in human fetal lung fibroblasts. Mutat Res 302: 97-102, 1993
109. Lynn S, Lai HT, Gurr JR, Jan KY: Arsenite retards DNA break rejoining by inhibiting DNA ligation. Mutagenesis 12: 353-358, 1997
110. Hughes MF: Arsenic toxicity and potential mechanisms of action. Toxicol Lett 133: 1-16, 2002
111. Li JH, Rossman TG: Comutagenesis of sodium arsenite with ultraviolet radiation in Chinese hamster V79 cells. Biol Met 4: 197-200, 1991
112. Lee TC, Oshimura M, Barrett JC: Comparison of arsenic-induced cell transformation, cytotoxicity, mutation and cytogenetic effects in Syrian hamster embryo cells in culture. Carcinogenesis 6: 1421-1426, 1985
113. Pershagen G, Nordberg G, Bjorklund NE: Carcinomas of the respiratory tract in hamsters given arsenic trioxide and/or benzo(a)pyrene by the pulmonary route. Environ Res 34: 227-241, 1984
114. Maier A, Schumann BL, Chang X, Talaska G, Puga A: Arsenic coexposure potentiates benzo[a]pyrene genotoxicity. Mutat Res 517: 101-111, 2002
115. Hu Y, Su L, Snow ET: Arsenic toxicity is enzyme specific and its affects on ligation are not caused by the direct inhibition of DNA repair enzymes. Mutat Res 408: 203-218, 1998
116. Zhao CQ, Young MR, Diwan BA, Coogan TP, Waalkes MP: Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proc Natl Acad Sci USA 94: 10907-10912, 1997
117. Mass MJ, Wang L: Arsenic alters cytosine methylation patterns of the promoter of the tumor suppressor gene p53 in human lung cells: A model for a mechanism of carcinogenesis. Mutat Res 386: 263-277, 1997
118. Kitchin KT: Recent advances in arsenic carcinogenesis: Modes of action, animal model systems, and methylated arsenic metabolites. Toxicol Appl Pharmacol 172: 249-261, 2001
119. Huang C, Ma WY, Li J, Goranson A, Dong Z: Requirement of Erk, but not JNK, for arsenite-induced cell transformation. J Biol Chem 274: 14595-14601, 1999
120. Wang CY, Mayo MW, Baldwin AS Jr: TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-kappaB. Science 274: 784-787, 1996
121. Wijeweera JB, Gandolfi AJ, Parrish A, Lantz RC: Sodium arsenite enhances AP-1 and NFkappaB DNA binding and induces stress protein expression in precision-cut rat lung slices. Toxicol Sci 61: 283-294, 2001
122. Angel P, Karin M: The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1072: 129-157, 1991
123. Dong Z, Watt RG, Sun Y, Colburn NH: Progressive elevation of AP-1 activity during preneoplastic-to-neoplastic progression as modeled in mouse JB6 cell variants. Int J Oncol 7: 359-364, 1995
124. Dong Z, Birrer MJ, Watts RG, Matrisian LM, Colburn NH: Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells. Proc Natl Acad Sci USA 91: 609-613, 1994
125. Huang C, Bode AM, Chen NY, Ma WY, Li J, Nomura M, Dong Z: Transactivation of AP-1 in AP-1-luciferase reporter transgenic mice by arsenite and arsenate. Anticancer Res 21: 261-267, 2001
126. Chen NY, Ma WY, Huang C, Ding M, Dong Z: Activation of PKC is required for arsenite-induced signal transduction. J Environ Pathol Toxicol Oncol 19: 297-305, 2000
127. Kharbanda S, Saxena S, Yoshida K, Pandey P, Kaneki M, Wang Q, Cheng K, Chen YN, Campbell A, Sudha T, Yuan ZM, Narula J, Weichselbaum R, Nalin C, Kufe D: Translocation of SAPK/JNK to mitochondria and interaction with Bcl-x(L) in response to DNA damage. J Biol Chem 275: 322-327, 2000
128. Davis RJ: MAPKs: New JNK expands the group. Trends Biochem Sci 19: 470-473, 1994
129. Kallunki T, Su B, Tsigelny I, Sluss HK, Derijard B, Moore G, Davis R, Karin, M: JNK2 contains a specificity-determining region responsible for efficient c-Jun binding and phosphorylation. Genes Dev 8: 2996-3007, 1994
130. Angel P, Hattori K, Smeal T, Karin M: The jun proto-oncogene is positively autoregulated by its product, Jun/AP-1. Cell 55: 875-885, 1988
131. Sanchez I, Hughes RT, Mayer BJ, Yee K, Woodgett JR, Avruch J, Kyriakis JM, Zon LI: Role of SAPK/ERK kinase-1 in the stress-activated pathway regulating transcription factor c-Jun. Nature 372: 794-798, 1994
132. Huang C, Ma WY, Li J, Dong Z: Arsenic induces apoptosis through a c-Jun NH2-terminal kinase-dependent, p53-independent pathway. Cancer Res 59: 3053-3058, 1999
133. Huang C, Li J, Ding M, Wang L, Shi X, Castranova V, Vallyathan V, Ju G, Costa M: Arsenic-induced NFkappaB transactivation through Erks- and JNKs-dependent pathways in mouse epidermal JB6 cells. Mol Cell Biochem 222: 29-34, 2001
134. Porter AC, Fanger GR, Vaillancourt RR: Signal transduction pathways regulated by arsenate and arsenite. Oncogene 18: 7794-7802, 1999
135. Kharbanda S, Saxena S, Yoshida K, Pandey P, Kaneki M, Wang Q, Cheng K, Chen YN, Campbell A, Sudha T, Yuan ZM, Narula J, Weichselbaum R, Nalin C, Kufe D: Translocation of SAPK/JNK to mitochondria and interaction with Bcl-x(L) in response to DNA damage. J Biol Chem 275: 322-327, 2000
136. Yamamoto K, Ichijo H, Korsmeyer SJ: BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol Cell Biol 19: 8469-8478, 1999
137. Qu W, Bortner CD, Sakurai T, Hobson MJ, Waalkes MP: Acquisition of apoptotic resistance in arsenic-induced malignant transformation: Role of the JNK signal transduction pathway. Carcinogenesis 23: 151-159, 2002
138. Ghosh S, May MJ, Kopp EB: NF-kappa B and Rel proteins: Evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16: 225-260, 1998
139. Baeuerle PA, Henkel T: Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 12: 141-179, 1994
140. Baldwin AS Jr: The NF-kappa B and I kappa B proteins: New discoveries and insights. Annu Rev Immunol 14: 649-683, 1996
141. Karin M, Delhase M: The I kappa B kinase (IKK) and NF-kappa B: Key elements of proinflammatory signalling. Semin Immunol 12: 85-98, 2000
142. Karin M, Ben-Neriah Y: Phosphorylation meets ubiquitination: The control of NF-[kappa]B activity. Annu Rev Immunol 18: 621-663, 2000
143. Karin M: The NF-kappa B activation pathway: its regulation and role in inflammation and cell survival. Cancer J Sci Am 4: S92-99, 1998
144. Gilmore TD: Clinically relevant findings. J Clin Invest 100: 2935-2936, 1997
145. Li JJ, Westergaard C, Ghosh P, Colburn NH: Inhibitors of both nuclear factor-kappaB and activator protein-1 activation block the neoplastic transformation response. Cancer Res 57: 3569-3576, 1997
146. Zhong H, SuYang H, Erdjument-Bromage H,Tempst P, Ghosh S: The transcriptional activity of NF-kappaB is regulated by the IkappaB-associated PKAc subunit through a cyclic AMP-independent mechanism. Cell 89: 413-424, 1997
147. Sizemore N, Leung S, Stark GR: Activation of phosphatidylinositol 3-kinase in response to interleukin-1 leads to phosphorylation and activation of the NF-kappaB p65/RelA subunit. Mol Cell Biol 19: 4798-4805, 1999
148. Fornace AJ Jr, Alamo I Jr, Hollander MC: DNA damage-inducible transcripts in mammalian cells. Proc Natl Acad Sci USA 85: 8800-8804, 1988
149. Wang XW, Zhan Q, Coursen JD, Khan MA, Kontny HU, Yu L, Hollander MC, O'Connor PM, Fornace AJ Jr, Harris CC: GADD45 induction of a G2/M cell cycle checkpoint. Proc Natl Acad Sci USA 96: 3706-3711, 1999
150. Yu J, Zhang L, Hwang PM, Rago C, Kinzler KW, Vogelstein B: Identification and classification of p53-regulated genes. Proc Natl Acad Sci USA 96: 14517-14522, 1999
151. Jin S, Zhao H, Fan F, Blanck P, Fan W, Colchagie AB, Fornace AJ Jr, Zhan Q: BRCA1 activation of the GADD45 promoter. Oncogene 19: 4050-4057, 2000
152. Chen F, Lu Y, Zhang Z, Vallyathan V, Ding M, Castranova V, Shi X: Opposite effect of NF-kappa B and c-Jun N-terminal kinase on p53-independent GADD45 induction by arsenite. J Biol Chem 276: 11414-11419, 2001
153. Vogt BL, Rossman TG: Effects of arsenite on p53, p21 and cyclin D expression in normal human fibroblasts - a possible mechanism for arsenite's comutagenicity. Mutat Res 478: 159-168, 2001
154. Hunter T, Pines J: Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell 79: 573-582, 1994
155. Simeonova PP, Wang S, Hulderman T, Luster MI: c-Src-dependent activation of the epidermal growth factor receptor and mitogen-activated protein kinase pathway by arsenic. Role in carcinogenesis. J Biol Chem 277: 2945-2950, 2002
156. Ansel J, Perry P, Brown J, Damm D, Phan T, Hart C, Luger T, Hefeneider S: Cytokine modulation of keratinocyte cytokines. J Invest Dermatol 94: 101S-107S, 1990
157. Owsianowski M, Busch FW, Bonnekoh B, Orfanos CE: Long-term cultured adult human keratinocytes secrete granulocyte-macrophage colony-stimulating factor but not interleukin-3 after cytokine exposure in vitro. Skin Pharmacol 4: 158-164, 1991
158. Vasunia KB, Miller ML, Puga A, Baxter CS: Granulocyte-macrophage colony-stimulating factor (GM-CSF) is expressed in mouse skin in response to tumor-promoting agents and modulates dermal inflammation and epidermal dark cell numbers. Carcinogenesis 15: 653-660, 1994
159. Robertson FM, Bijur GN, Oberyszyn AS, Pellegrini AE, Boros LG, Sabourin CL, Oberyszyn TM: Granulocyte-macrophage colony stimulating factor gene expression and function during tumor promotion. Carcinogenesis 15: 1017-1029, 1994
160. Vahter M: What are the chemical forms of arsenic in urine, and what can they tell us about exposure? Clin Chem 40: 679-680, 1994
161. Healy SM, Zakharyan RA, Aposhian HV: Enzymatic methylation of arsenic compounds: IV. In vitro and in vivo deficiency of the methylation of arsenite and monomethylarsonic acid in the guinea pig. Mutat Res 386: 229-239, 1997
162. Hamadeh HK, Vargas M, Lee E, Menzel DB: Arsenic disrupts cellular levels of p53 and mdm2: A potential mechanism of carcinogenesis. Biochem Biophys Res Commun 263: 446-449, 1999
163. Salazar AM, Ostrosky-Wegman P, Menendez D, Miranda E, Garcia-Carranca A, Rojas E: Induction of p53 protein expression by sodium arsenite. Mutat Res 381: 259-265, 1997
164. Shen L, Chen TX, Wang YP, Lin Z, Zhao HJ, Zu YZ, Wit G, Ying DM: As2O3 induces apoptosis of the human B lymphoma cell line MBC-1. J Biol Regul Homeost Agents 14: 116-119, 2000
165. Yih LH, Ho IC, Lee TC: Sodium arsenite disturbs mitosis and induces chromosome loss in human fibroblasts. Cancer Res 57: 5051-5059, 1997
166. Yih LH, Lee TC: Effects of exposure protocols on induction of kinetochore-plus and -minus micronuclei by arsenite in diploid human fibroblasts. Mutat Res 440: 75-82, 1999